Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 reporting a proposed sale of 3,203 common shares acquired the same day by exercise of stock options. The shares have an aggregate market value of $1,107,373.19 and are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ. The filing lists total shares outstanding of 22,289,014, so the proposed sale represents a small fraction of the company stock. The acquisition was paid in cash. The filing also discloses multiple 10b5-1 sales by Rebecca Taub and Paul A. Friedman in mid-July 2025 totaling 60,377 shares with combined gross proceeds of $21,316,990.08.
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 reports a proposed sale of 3,200 common shares through Morgan Stanley Smith Barney LLC on 08/11/2025 for an aggregate market value of $1,106,336.00. The filing shows 22,289,014 shares outstanding and lists NASDAQ as the exchange.
The shares were acquired on 08/11/2025 by exercise of stock options from the issuer, paid in cash. The filing also discloses multiple recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman during July 2025 totaling 60,377 shares with combined gross proceeds of about $21.3 million.
Madrigal Pharmaceuticals’ Q2-25 10-Q shows the company’s first full quarter of Rezdiffra commercialization driving a dramatic top-line inflection. Net product revenue reached $212.8 m for the quarter and $350.1 m YTD, versus $14.6 m in the prior-year periods. Cost of sales was only $13.6 m YTD, yielding a gross margin above 96%, but heavy commercial scale-up spending pushed operating expenses to $476.6 m (up 45% YoY). Consequently, the H1 operating loss narrowed to $126.5 m from $314.6 m, with a GAAP net loss of $115.5 m (-$5.22/sh).
Cash, cash equivalents and marketable securities totalled $802.0 m at 30 Jun 25, down modestly from $931.3 m at year-end after $136 m operating cash burn and $212 m net investment inflow. Inventory rose to $63.5 m as launch stock builds. Accounts receivable increased to $79.2 m, and gross-to-net reserves expanded to $52.3 m, reflecting payer rebates and copay assistance.
Liabilities were $319.4 m, including $118.4 m outstanding on the Hercules loan. Post-quarter, Madrigal replaced this facility with a new $350 m initial draw (up to $500 m total) Blue Owl secured term loan maturing 2030, subject to a $100 m minimum cash covenant.
22.29 m shares were outstanding on 1 Aug 25. Management emphasises ongoing U.S. launch execution, EU regulatory progress, and outcome trials needed for full Rezdiffra approval and label expansion.
Kenneth Bate, Director at Madrigal Pharmaceuticals (MDGL), reported two significant equity transactions on June 20, 2025:
- Received 715 restricted stock units (RSUs) at $0, bringing total direct common stock ownership to 2,627 shares
- Granted stock options to purchase 1,290 shares at an exercise price of $285.73 per share
Both the RSUs and stock options are scheduled to vest at the company's 2026 annual stockholder meeting, contingent on Bate's continued service as director. The stock options have a ten-year term, expiring on June 20, 2035. The transactions were reported via Form 4 filing, with Mardi Dier signing as attorney-in-fact on June 24, 2025.
Madrigal Pharmaceuticals (MDGL) filed a Form 4 disclosing new equity awards to director Richard S. Levy dated 06/20/2025.
- Levy received 715 restricted stock units (coded “A”) at no cost. The RSUs vest on the date of the 2026 annual meeting, conditional on his continued service.
- He was also granted 1,290 stock options with a $285.73 exercise price and a 06/20/2035 expiration. These options vest 100 % at the 2026 annual meeting, subject to the same service requirement.
Following the transactions, Levy directly owns 21,197 common shares and 1,290 options. No open-market purchases or sales were reported.